PDS Biotechnology price target lowered to $3 from $5 at B. Riley

B. Riley lowered the firm’s price target on PDS Biotechnology (PDSB) to $3 from $5 and keeps a Buy rating on the shares. The shares remain attractively valued with near-zero EV that fails to reflect impact of this recent strategic pivot on enrollment size, efficacy endpoint durations and an enriched p16+ve population with limited competing trials, the analyst tells investors in a research note. TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research tools you ...